LibraryMusculoskeletal & Rheumatology· 35 of 60
Musculoskeletal & Rheumatology

Osteoarthritis

~11 min read4 sections
OAcartilageHeberden Bouchard
🎯 Drill Musculoskeletal & Rheumatology
Contents (4)

Osteoarthritis (OA) is a chronic, progressive degenerative joint disease characterized by mechanical breakdown of articular cartilage, subchondral bone remodeling, and formation of osteophytes, resulting in joint dysfunction and pain. It represents the most common form of arthritis globally, affecting approximately 10% of men and 18% of women over age 60, with prevalence increasing dramatically with advancing age and obesity. OA is a leading cause of disability worldwide, affecting quality of life through pain, stiffness, and functional limitation, with the knee, hip, hand, and spine being the most commonly involved joints. While historically considered a simple "wear-and-tear" disease, modern understanding recognizes OA as a complex, multifactorial condition involving biochemical inflammation, genetic predisposition, biomechanical factors, and systemic metabolic dysfunction. Understanding OA pathophysiology, diagnostic approach, and evidence-based management is essential for USMLE Step 2 CK, as board questions frequently test distinction from inflammatory arthropathies, imaging interpretation, and treatment decisions.

The pathophysiology of osteoarthritis involves a complex interplay of biomechanical stress, inflammatory mediators, enzymatic degradation, and aberrant bone remodeling that progressively destroys the joint microarchitecture:

  • Cartilage degradation through protease activation: In the early phase of OA, mechanical stress and minor joint injury trigger release of damage-associated molecular patterns (DAMPs) and reactive oxygen species (ROS). These signals activate resident chondrocytes and infiltrating macrophages to produce matrix metalloproteinases (MMPs) (particularly MMP-2, MMP-9, and MMP-13) and ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) proteases. These enzymes degrade the extracellular matrix components—specifically type II collagen (the primary structural protein of cartilage) and proteoglycans (especially aggrecan), which provide hydration and shock absorption. The loss of these structural components depletes the glycosaminoglycan (GAG) content of cartilage, reducing its water-binding capacity and mechanical stiffness, leading to fibrillation and progressive erosion. This proteolytic cascade is perpetuated by pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) produced by chondrocytes and synovial macrophages, creating a self-amplifying cycle of destruction.
  • Synovial inflammation and low-grade inflammatory response: Contrary to the traditional view of OA as non-inflammatory, modern evidence demonstrates significant synovial inflammation in OA joints. Degradation products from cartilage (including type II collagen fragments, fibronectin fragments, and aggrecan epitopes) act as DAMPs that activate toll-like receptors (TLRs) and NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome in synovial resident macrophages and fibroblasts. This inflammasome activation leads to cleavage and release of caspase-1, which activates pro-IL-1β and pro-IL-18 into their mature, secreted forms. IL-1β is the cardinal inflammatory driver in OA—it suppresses anabolic pathways (reduced collagen and proteoglycan synthesis via decreased RUNX2 and SOX9 transcription factor activity) while amplifying catabolic cascades (increased MMP and ADAMTS expression). Additionally, the damaged synovium produces complement components (particularly C3a and C5a), chemokines (CCL2, CXCL8), and adhesion molecules that recruit neutrophils and monocytes, perpetuating inflammation despite the absence of systemic elevation of inflammatory markers in most OA patients.
  • Subchondral bone changes and osteophyte formation: OA involves not only cartilage loss but also profound remodeling of the underlying bone compartment. In early OA, subchondral bone experiences increased resorption and abnormal remodeling due to elevated RANKL (receptor activator of nuclear factor κB ligand) expression by osteoblasts and synovial cells, which promotes osteoclast activation and bone resorption. This leads to increased subchondral bone turnover, microfractures, bone marrow lesions (visible on MRI), and paradoxical increases in bone density in some regions—a phenomenon termed "subchondral sclerosis." Simultaneously, osteophyte (bone spur) formation occurs at the joint margins, driven by TGF-β signaling and aberrant Wnt/β-catenin pathway activation. These osteophytes represent abnormal bone formation by osteoblasts at the cartilage-bone interface and ligamentous insertions, likely representing a maladaptive attempt to stabilize the degenerating joint but ultimately contributing to joint incongruity and mechanical dysfunction. The loss of normal subchondral bone compliance also increases stress transmission to cartilage, accelerating its degradation in a biomechanical feedback loop.
  • Chondrocyte dysfunction and loss of anabolic capacity: Rather than passive wear, OA involves active chondrocyte pathology. Healthy chondrocytes maintain cartilage through constant synthesis of type II collagen and proteoglycans, balanced against controlled matrix remodeling. In OA, chondrocytes undergo phenotypic alterations including: (1) increased expression of catabolic enzymes (MMPs, ADAMTS) and pro-inflammatory mediators (IL-1β, TNF-α, COX-2, NOS2); (2) hypertrophy and terminal differentiation, with upregulation of alkaline phosphatase, type X collagen, and MMP-13 (reminiscent of endochondral ossification); (3) senescence, characterized by p16/p21 upregulation, telomere shortening, and resistant-to-apoptosis phenotype; and (4) impaired anabolic signaling, with reduced response to IGF-1 and TGF-β, and decreased expression of anabolic transcription factors. These changes are driven by biomechanical stress (excessive or abnormal loading), age-related decline in regenerative capacity, and chronic exposure to inflammatory mediators. The net result is a chondrocyte unable to synthesize and maintain the extracellular matrix, accelerating net cartilage loss.
  • Genetic and epigenetic predisposition: OA has substantial genetic components, with heritability estimates of 39-65% depending on joint and population studied. GWAS (genome-wide association studies) have identified >100 genetic loci associated with OA risk, including variants in genes encoding: (1) cartilage matrix proteins (COL11A1, COL2A1); (2) signaling pathways (GDF5, FRZB, CHST11); (3) inflammatory mediators and receptors (IL-6, GDF5); and (4) metabolic regulators (APOE, BMI-related loci). Additionally, epigenetic modifications (DNA methylation, histone acetylation, microRNA dysregulation) alter gene expression in chondrocytes without changing DNA sequence, contributing to the age-dependent and environment-responsive nature of OA. For example, hypermethylation of genes encoding anabolic factors and hypomethylation of catabolic genes promotes the OA phenotype. These genetic and epigenetic factors explain why some individuals develop severe OA despite minimal joint trauma, while others tolerate substantial mechanical stress without significant cartilage loss.
  • Metabolic dysfunction and systemic factors: Emerging evidence links systemic metabolic factors to OA pathogenesis. Obesity increases OA risk through mechanisms beyond simple mechanical load: adipose tissue produces leptin (pro-inflammatory) and reduced adiponectin (anti-inflammatory), shifting the balance toward inflammation. Metabolic endotoxemia from altered gut microbiota in obesity increases circulating lipopolysaccharides (LPS), activating TLR4 and promoting systemic inflammation that extends to joint tissues. Additionally, insulin resistance and hyperglycemia promote formation of advanced glycation end products (AGEs) that cross-link cartilage proteins and promote inflammation via RAGE (receptor for AGEs) signaling. Systemic hypertension may increase OA risk through endothelial dysfunction and reduced vasodilatory capacity, compromising cartilage nutrition. These metabolic factors explain why OA is increasingly recognized as a systemic disease associated with cardiovascular disease, metabolic syndrome, and cognitive decline in some populations.

  • Age: Age is the strongest risk factor for primary OA, with exponential increase in prevalence after age 50-60. Aging is associated with: accumulation of chondrocyte senescence, telomere shortening, reduced regenerative capacity, increased mitochondrial dysfunction and ROS production, altered inflammatory response ("inflammaging"), and accumulated DNA damage. The intrinsic decline in chondrocyte anabolic function with age makes joints increasingly vulnerable to the catabolic effects of inflammatory stimuli that might be tolerated in younger individuals.
  • Obesity: Elevated BMI is a major modifiable risk factor, particularly for knee and hip OA. Obesity contributes through: (1) mechanical factors—increased joint loading (particularly in weight-bearing joints); (2) metabolic inflammation—adipose tissue-derived pro-inflammatory cytokines (leptin, IL-6, TNF-α) and reduced anti-inflammatory adipokines (adiponectin); (3) altered lipid metabolism—increased circulating fatty acids promote inflammasome activation; and (4) metabolic endotoxemia—increased circulating LPS promotes systemic inflammation. Notably, obesity increases OA risk in non-weight-bearing joints (hand, spine), supporting the metabolic contribution beyond mechanical load. Weight loss interventions demonstrably reduce OA pain and progression.
  • Female sex and estrogen status: Women have higher prevalence of hand OA and generalized OA (multiple joints) compared to men. The increased prevalence in postmenopausal women suggests estrogen deficiency contributes, as estrogen has anti-inflammatory effects and supports chondrocyte function. Estrogen receptors are expressed on chondrocytes and synovial cells, and estrogen deficiency leads to increased susceptibility to cartilage damage and reduced regenerative capacity.
  • Prior joint injury and mechanical trauma: Acute ligamentous injuries (particularly anterior cruciate ligament [ACL] tear), meniscal damage, fractures involving the articular surface, and other intra-articular injuries substantially increase OA risk in that joint, often within 10-15 years. The mechanism involves: acute inflammatory cascade, altered joint biomechanics with abnormal load distribution, and persistent low-grade inflammation. Post-traumatic OA can develop even with successful surgical reconstruction if the joint mechanics remain altered.
  • Chronic repetitive joint stress and occupational factors: Specific occupational and recreational activities involving repetitive high-impact loading or abnormal joint mechanics increase OA risk. Examples include: prolonged kneeling or squatting (knee OA), repetitive gripping or pinching (hand OA), and professional ballet or long-distance running. However, moderate regular exercise appears protective, likely because it maintains muscle strength, proprioception, and synovial fluid nutrition.
  • Genetic predisposition: Family history of OA (particularly early-onset or generalized OA) indicates genetic contributions. Specific genetic variants in COL2A1 (type II collagen), GDF5 (growth and differentiation factor 5), FRZB, and other genes modulate OA susceptibility. Rare mutations in type II collagen or other cartilage proteins cause early-onset familial OA with severe phenotypes.
  • Anatomical and biomechanical factors: Malalignment (varus/valgus deformity, particularly in the knee), joint instability, leg length discrepancy, and abnormal joint morphology (dysplasia, cam/pincer morphology in hip) alter load distribution and accelerate cartilage breakdown. Developmental dysplasia of the hip (DDH) and femoroacetabular impingement (FAI) are strong risk factors for early-onset hip OA.
  • Secondary causes of OA: Several underlying conditions predispose to premature OA development:
  • Inflammatory arthropathies: Rheumatoid arthritis, psoriatic arthritis, and other chronic inflammatory conditions cause secondary OA through ongoing joint inflammation and cartilage destruction.
  • Metabolic disorders: Hemochromatosis (iron deposition in cartilage), ochronosis (alkaptonuria with pigment deposition), gout, pseudogout (calcium pyrophosphate deposition disease [CPPD]), and hyperparathyroidism accelerate cartilage degeneration.
  • Avascular necrosis (AVN): Collapse of bone and subsequent joint incongruity rapidly leads to OA.
  • Previous septic arthritis: Bacterial infection causes permanent cartilage damage even after successful treatment.
  • Endocrine disorders: Diabetes mellitus and acromegaly increase OA risk through metabolic and growth-related mechanisms.
  • Joint hypermobility syndromes: Ehlers-Danlos syndrome and hypermobility spectrum disorders predispose to early OA due to abnormal cartilage matrix and joint instability.

  • Joint pain: The cardinal symptom of OA is pain localized to affected joint(s), characteristically worse with activity and weight-bearing and improved with rest. The pain is typically mechanical in nature—it increases with repetitive movement and improves with relative immobility, distinguishing it from inflammatory arthritis pain. Early in OA, pain may be intermittent and activity-related; as disease progresses, pain becomes more constant and may occur at rest or awaken patient from sleep. The pain arises from: nociceptor activation in synovial tissue (the most pain-sensitive structure, containing high density of nerve endings), periosteal inflammation at osteophyte sites, joint capsule distension, bone marrow lesions, and muscle spasm secondary to joint dysfunction. Importantly, there is often poor correlation between structural severity on imaging and pain severity, suggesting that pain involves factors beyond cartilage loss alone, including synovial inflammation, bone marrow lesions, and neuropathic mechanisms.
  • Morning stiffness and gel phenomenon: Patients frequently report stiffness upon waking or after prolonged immobility (e.g., prolonged sitting), typically lasting less than 30 minutes (in contrast to inflammatory arthropathies where morning stiffness exceeds 1-2 hours). This stiffness is attributed to: redistribution of synovial fluid from the joint space into surrounding tissues during rest, increased synovial fluid viscosity after immobility, and muscle guarding due to pain. Movement gradually redistributes fluid and lubricates the joint, providing symptomatic relief—the "gel phenomenon." With advanced disease, stiffness may become more pronounced.
  • Functional limitation and loss of range of motion: As OA progresses, patients develop objective limitation in active and passive range of motion in affected joints, leading to disability and reduced functional capacity. Contractures can develop from chronic pain-mediated muscle guarding and fibrosis of joint capsule and synovium. Patients report difficulty with specific activities: climbing stairs and walking (knee/hip OA), gripping objects and fine motor tasks (hand OA), and neck mobility and upper extremity function (cervical spine OA). These functional limitations are major drivers of the health burden of OA and often prompt patients to seek medical care more than pain alone.
  • Swelling and joint effusion: Affected joints may demonstrate swelling from joint effusion (synovial fluid accumulation), synovial hypertrophy, and soft tissue edema. In the knee, effusions can be detected by clinical examination (ballottement test, bulge sign) or imaging. Effusions in OA typically contain non-inflammatory fluid (WBC <2000/μL), though some patients develop mild elevations in WBC count reflecting synovial inflammation. Bony swelling from osteophytes (particularly in hand OA) creates the characteristic hard nodules: Heberden nodes (PIP joints) and Bouchard nodes (DIP joints).
  • Crepitus: Many patients report or clinicians detect crepitus (grinding or cracking sensation) with joint movement, caused by irregular cartilage surface, osteophytes, or loose bodies in the joint space. This is distinguishable from the inflammatory joint sounds and is usually painless, though crepitus accompanying pain suggests more significant cartilage damage.
  • Physical examination findings:
  • Bony enlargement: Hard, non-tender swelling at joint margins from osteophytes; particularly prominent in hand OA (Heberden nodes, Bouchard nodes) and in knee OA (osteophytes palpable at joint margins)
  • Limited range of motion: Objective reduction in active and passive ROM in affected joints, sometimes with end-feel that is hard and bony (from osteophytes) rather than soft
  • Joint effusion: Detectable in knee (ballottement, bulge sign); synovial thickening may be palpable
  • Muscle atrophy: Particularly evident in

Related topics

← Back to library